Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia: a population-based case control study from the Nordic countries
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Saarinen-Pihkala, U M
MetadataShow full item record
CitationBone Marrow Transplant. 1999, 23(6):555-60
AbstractThis study compares allogeneic BMT with conventional chemotherapy for childhood ALL in second remission. Seventy-five children were transplanted between July 1981 and December 1995. For each patient two control patients matching the following criteria were selected from the Nordic database of ALL: (1) time of diagnosis, (2) T vs. non-T ALL, (3) site of relapse, (4) initial risk group, (5) sex and (6) relapse < or > or =6 months after cessation of therapy. The minimal time of follow-up was 24 months. Mortality rate in CR2, leukemic relapse rate and the proportion in continued second remission were 16/75 (21%), 22/75 (29%) and 37/75 (50%), respectively. P2.-EFS for the BMT group was significantly better than that for the control group (0.40 vs. 0.23, P = 0.02). Children transplanted for bone marrow relapses in particular had a higher P2.-EFS (0.35 vs. 0.15 for the control group, P<0.01). Also, children grafted for early BM relapses had a higher P2.-EFS (0.32 vs. 0.11 for the control group P = 0.01). The outcome was similar when children were transplanted after early or late relapse. Also, there was no difference in outcome between the BMT and the chemotherapy group for children with late relapses. We conclude that allogeneic BMT with an HLA-identical sibling donor or other family donor should be performed in children relapsing in bone marrow during therapy or within 6 months of discontinuing therapy.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: a retrospective case-control study in the Nordic countries. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
- Authors: Saarinen UM, Mellander L, Nysom K, Ringden O, Schroeder H, Glomstein A, Gustafsson G
- Issue date: 1996 Mar
- Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
- Authors: Parsons SK, Castellino SM, Lehmann LE, Eickhoff CE, Tarbell NJ, Sallan SE, Weinstein HJ, Billett AL
- Issue date: 1996 May
- Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative?
- Authors: Borgmann A, Baumgarten E, Schmid H, Dopfer R, Ebell W, Göbel U, Niethammer D, Gadner H, Henze G
- Issue date: 1997 Dec
- Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
- Authors: Uderzo C, Dini G, Locatelli F, Miniero R, Tamaro P
- Issue date: 2000 Nov
- Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group.
- Authors: Borgmann A, Hartmann R, Schmid H, Klingebiel T, Ebell W, Göbel U, Peters C, Gadner H, Henze G
- Issue date: 1995 Apr